New Antibiotic Found in Parasitic Worms Kills Drug-Resistant Bacteria

An Antibiotic Found in Parasitic Worms may be the newest weapon against infections that no longer answer to modern medicine. Researchers at NYU Abu Dhabi have rebuilt a natural compound from scratch after realizing its long-accepted structure was wrong, and the corrected molecule killed drug-resistant strains of a pneumonia-causing bacterium in laboratory tests, according to the university's announcement.

The Worm, the Bacterium, and the Killing Wave

The compound comes from an unlikely partnership. A bacterium named Xenorhabdus lives inside the gut of parasitic worms that infect insects, and when the worm slips into an insect larva it releases its bacterial partner in waves. The first wave suppresses the larva's immune system, the second kills the insect, and the third — the one scientists care about — sterilizes the carcass so rival microbes cannot claim it. The antibiotic in that third wave is the newly resurrected compound, rhabdobranin.

Getting it into the lab was the hard part. Scientists had identified the genes that appeared to build the compound years ago, but nobody had managed to isolate it and prove it could kill harmful bacteria. When the team finally synthesized it in September 2026, they discovered that the structure proposed in earlier research did not match the real molecule — and that the mistaken version was completely inactive. "The incorrect one is a dead compound — it doesn't do anything," the study's lead researcher, postdoctoral scientist Woonkee Jo, told Washington Square News. "But the correct structure really is active against some of the deadliest pathogens we know."

Why a Worm's Chemistry Matters to Your Medicine Cabinet

An Antibiotic Found in Parasitic Worms attacks in a straightforward but brutal way: it stops bacteria from making proteins, the process they need to grow and survive. Laboratory tests found it could kill several types of harmful bacteria, including carbapenem-resistant strains of Klebsiella pneumoniae — bacteria that resist carbapenems, a class of powerful antibiotics reserved for serious infections. Finding a new molecule that still works against such pathogens is exactly what infectious-disease researchers have been asking for.

The work, published in the Journal of the American Chemical Society, was led from the Healy laboratory with collaborators in Germany and China. Senior author Alan R. Healy said the result highlights the potential of looking in unexpected places for new antibiotics, and that further study is needed before the compound can become a starting point for drug development. Genetic blueprints like the one behind this discovery could offer a cheaper scouting route, since they point to antibiotics that nature already built, rather than requiring chemists to invent from zero.

The timing is urgent. A landmark analysis published in a major medical journal attributed about one point three million deaths in a single year to infections from drug-resistant bacteria, and resistant strains keep spreading through hospitals and communities. For a generation raised on warnings about the end of effective antibiotics, the finding is a reminder that the pipeline is not empty — it just looks different from the classic soil-screening era that produced penicillin and its descendants.

The worm-derived compound is not the only new angle on the problem this year. In July, a separate team used electron microscopy to catch the familiar antibiotic doxycycline working through hidden mechanisms nobody had seen before, a sign that even old drugs still hold surprises. The Abu Dhabi team's approach ran in the opposite direction: rather than re-examining a known drug, they reconstructed a natural molecule whose blueprint had been sitting, misread, in genetic databases for years.

For this Antibiotic Found in Parasitic Worms, the journey from petri dish to pharmacy will be long, and nobody on the team pretends otherwise. The compound faces years of safety and efficacy testing before it could become a medicine, and the economics of antibiotic development remain brutal — the lead researcher noted that the bar is high to convince pharmaceutical companies to invest in new antibiotic programs. The next step is to study how the molecule can be tuned and whether its protein-blocking mechanism can inspire entirely new classes of treatment.

For now, the result is proof that strange places still hide working medicine: a parasitic worm's chemical warfare kit, decoded and corrected, killing bacteria that defeat today's strongest drugs. Readers can also see how everyday choices interact with the antibiotics we already have, in reporting on how diet affects antibiotic recovery, plus how young people are reshaping where they get care — and why scientists keep finding second jobs for existing medicines.